• ?Welgene Biotech is a leading life science distributor focused on molecular biology and cell biology
• ?TruePrime™ and SunScript™ product families comprise powerful tools addressing key challenges in next generation sequencing (NGS) and single cell analysis (SCA)
Madrid, Spain and Heidelberg, Germany, June 11th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio in Taiwan with Welgene Biotech.
Under the terms of the agreement, SYGNIS has granted Welgene Biotech the non-exclusive rights to promote, market and sell TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Taiwan.
TruePrime™ products are based on the combination of SYGNIS’ proprietary DNA primase “TthPrimPol” and Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
SYGNIS’ SunScript™ product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Welgene Biotech is a specialist provider offering a broad portfolio of innovative research reagents and state-of-the-art instruments in the field of molecular biology as well as cell biology applications to customers in Taiwan.
"We are very pleased that we are able to announce the second distribution agreement in Asia with Welgene Biotech, which significantly strengthens our presence in the Asian market and perfectly position our products in the rapidly growing biotechnology industry in Taiwan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Welgene Biotech complements our fast growing list of leading international distribution partners. The high interest and demand in our proprietary product and technology families fuel our efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the molecular biology industry throughout the world."
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions: SunScript™ RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions whereas SunScript™ RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and two own product lines on the market: TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
Help employers find you! Check out all the jobs and post your resume.
• ?TruePrime™ and SunScript™ product families comprise powerful tools addressing key challenges in next generation sequencing (NGS) and single cell analysis (SCA)
Madrid, Spain and Heidelberg, Germany, June 11th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non-exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio in Taiwan with Welgene Biotech.
Under the terms of the agreement, SYGNIS has granted Welgene Biotech the non-exclusive rights to promote, market and sell TruePrime™ products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Taiwan.
TruePrime™ products are based on the combination of SYGNIS’ proprietary DNA primase “TthPrimPol” and Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
SYGNIS’ SunScript™ product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Welgene Biotech is a specialist provider offering a broad portfolio of innovative research reagents and state-of-the-art instruments in the field of molecular biology as well as cell biology applications to customers in Taiwan.
"We are very pleased that we are able to announce the second distribution agreement in Asia with Welgene Biotech, which significantly strengthens our presence in the Asian market and perfectly position our products in the rapidly growing biotechnology industry in Taiwan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Welgene Biotech complements our fast growing list of leading international distribution partners. The high interest and demand in our proprietary product and technology families fuel our efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the molecular biology industry throughout the world."
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
About TruePrime™
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification technology and one of the key products in SYGNIS’ portfolio. TruePrime™ is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScript™ Reverse Transcriptase will be available in two versions: SunScript™ RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions whereas SunScript™ RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi®, licensed to an industry leading partner and two own product lines on the market: TruePrime™ based on its proprietary TruePrime™ technology for whole genome amplification and SunScript™ Reverse Transcriptase to convert genetic information from RNA molecules back to DNA. Both product lines are addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications.
Help employers find you! Check out all the jobs and post your resume.
